Aria PharmaceuticalsMore Progress, with More ConfidenceBy: Andrew A Radin, CEO & Co-founder, Aria PharmaceuticalsDec 19, 2022Dec 19, 2022
Aria PharmaceuticalsWe Must Unblock the Sharing of DataBy: Aaron C. Daugherty, VP of Discovery, Aria PharmaceuticalsNov 9, 2022Nov 9, 2022
Aria PharmaceuticalsMoving the dialogue forward: The need for better AI integration in drug discoveryBy: Andrew A Radin, CEO & Co-founder, Aria PharmaceuticalsMar 16, 2022Mar 16, 2022
Aria PharmaceuticalsA New Era of Hope for Idiopathic Pulmonary FibrosisBy: Anjali Pandey, Ph.D.Sep 30, 2021Sep 30, 2021
Aria PharmaceuticalsWhat’s In A Name? Artistry and Sound Science!By: Andrew A. RadinMay 26, 2021May 26, 2021
Aria PharmaceuticalsR&D Is Changing And I’m On Boardby: Mark Eller, Ph.D. SVP of R&D, twoXARMar 31, 2021Mar 31, 2021
Aria PharmaceuticalsThis Year’s JPM Healthcare Conference Should Give Our Industry ConfidenceAndrew A. Radin CEO, twoXAR PharmaceuticalsJan 21, 2021Jan 21, 2021
Aria PharmaceuticalsLooking forward to 2021 at twoXARAndrew A. Radin CEO, twoXAR PharmaceuticalsDec 16, 2020Dec 16, 2020
Aria PharmaceuticalsWhy twoXAR Pharmaceuticals isn’t working on COVID-19by: Andrew A. Radin CEO, twoXAROct 28, 2020Oct 28, 2020